PETAH TIKVA, ISRAEL and BOCA RATON, FL—Biobeat Technologies, Ltd., developer of the first FDA-cleared, 24-hour ambulatory blood pressure monitoring (ABPM) system that is a patch-worn, cuff-less solution for diagnosis and…
Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 CAMBRIDGE, MA—(GLOBE NEWSWIRE)—ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company…
VALENCIA, CA—SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, announced that it has raised $140 million in private financing, that includes $25 million…
Financing led by Ally Bridge Group, with participation from SOLVE FSHD, a venture philanthropy organization Lead program, EPI-321, is the first clinical application of epigenetic modulation in neuromuscular diseases, with…
To fund completion of the EMPOWER Trial U.S. pivotal study and continue the commercialization of the Carillon Mitral Contour System KIRKLAND, WA—Cardiac Dimensions®, a leader in minimally invasive treatments for…
Latest Funding Accelerates the Company’s Commercial Expansion SAN JOSE, CA—VitalConnect®, Inc., a leader in biosensor technology, specializing in ambulatory cardiac monitoring, today announced the closing of $100 million in financing…
